Defunct Company
Total Trials
4
As Lead Sponsor
1
As Collaborator
3
Total Enrollment
3,372
NCT02273635
Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
Phase: Phase 1/2
Role: Lead Sponsor
Start: Sep 30, 2014
Completion: Apr 30, 2017
NCT03735550
Effectiveness of Liquid Crystal Contact Thermography in Detecting Pathological Changes in Female Breasts
Phase: N/A
Role: Collaborator
Start: Feb 1, 2017
Completion: Jan 31, 2019
NCT03679455
A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1
Phase: Phase 2
Start: Sep 21, 2018
Completion: Dec 31, 2022
NCT03697655
Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma
Start: Dec 10, 2018
Completion: Jul 31, 2024